INS and Hyperglycemia: We find that AAV2/8-insulin gene therapy can indeed correct hyperglycaemia in both of these models of diabetes, but that the dose requirements for success in autoimmune, spontaneously diabetic NOD mice is 7–10-fold higher than in non-autoimmune C57BL/6 mice.